University of Wollongong

Research Online
Australian Institute for Innovative Materials Papers

Australian Institute for Innovative Materials

1-1-2018

The serine protease HtrA1 contributes to the formation of an extracellular
25-kDa apolipoprotein E fragment that stimulates neuritogenesis
Sonia Sanz Munoz
University of Wollongong, ssm886@uowmail.edu.au

Hongyun Li
University of Wollongong, hongyun@uow.edu.au

Kalani R. Ruberu
University of Wollongong, kalani@uow.edu.au

Qian Chu
Salk Institute for Biological Studies

Alan Saghatelian
Salk Institute for Biological Studies

See next page for additional authors

Follow this and additional works at: https://ro.uow.edu.au/aiimpapers
Part of the Engineering Commons, and the Physical Sciences and Mathematics Commons

Recommended Citation
Sanz Munoz, Sonia; Li, Hongyun; Ruberu, Kalani R.; Chu, Qian; Saghatelian, Alan; Ooi, Lezanne; and Garner,
Brett, "The serine protease HtrA1 contributes to the formation of an extracellular 25-kDa apolipoprotein E
fragment that stimulates neuritogenesis" (2018). Australian Institute for Innovative Materials - Papers.
3014.
https://ro.uow.edu.au/aiimpapers/3014

Research Online is the open access institutional repository for the University of Wollongong. For further information
contact the UOW Library: research-pubs@uow.edu.au

The serine protease HtrA1 contributes to the formation of an extracellular 25-kDa
apolipoprotein E fragment that stimulates neuritogenesis
Abstract
Apolipoprotein-E (apoE) is a glycoprotein highly expressed in the brain, where it appears to play a role in
lipid transport, β-amyloid clearance, and neuronal signaling. ApoE proteolytic fragments are also present
in the brain, but the enzymes responsible for apoE fragmentation are unknown, and the biological activity
of specific apoE fragments remains to be determined. Here we utilized SK-N-SH neuroblastoma cells
differentiated into neurons with all-trans-retinoic acid (ATRA) to study extracellular apoE proteolysis. ApoE
fragments were detectable in culture supernatants after 3 days, and their levels were increased for up to 9
days in the presence of ATRA. The concentration of apoE fragments was positively correlated with levels
of the neuronal maturation markers (PSD95 and SMI32). The most abundant apoE fragments were 25and 28-kDa N-terminal fragments that both contained sialylated glycosylation and bound to heparin. We
detected apoE fragments only in the extracellular milieu and not in cell lysates, suggesting that an
extracellular protease contributes to apoE fragmentation. Of note, siRNAmediated knockdown of hightemperature requirement serine peptidase A1 (HtrA1) and a specific HtrA1 inhibitor reduced apoE 25-kDa
fragment formation by 41 and 86%, respectively. Recombinant 25-kDa fragment apoE and full-length apoE
both stimulated neuritogenesis in vitro, increasing neuroblastoma neurite growth by more than 2-fold over
a 6-day period. This study provides a cellular model for assessing apoE proteolysis, indicates that HtrA1
regulates apoE 25-kDa fragment formation under physiological conditions, and reveals a new
neurotrophic function for the apoE 25-kDa fragment.
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Apolipoprotein-E (apoE)6 is a ⬃35-kDa glycoprotein that is
highly expressed in the brain, where it is thought to play a role in
lipid transport, ␤-amyloid (A␤) clearance, and neuronal signaling (1). ApoE consists of a ⬃25-kDa four-helix bundle N-terminal domain and a ⬃10-kDa C-terminal domain. A short
hinge region containing a single O-linked glycan separates
these domains. The APOE genotype is the greatest known
genetic risk factor for AD, whereby possession of one or two
copies of the APOE⑀4 allele confers a 3- or 10-fold increase,
respectively, in AD risk compared with APOE⑀3 homozygotes
(2). In contrast, the APOE⑀2 allele is associated with decreased
AD risk (2). These APOE genotypes produce the three major
apoE isoforms, apoE2, apoE3, and apoE4, which differ in their
Cys/Arg composition at positions 112 and 158. ApoE2 contains
Cys112 and Cys158; apoE3 contains Cys112 and Arg158; and
apoE4 contains Arg112 and Arg158 (3).
ApoE is present in the central nervous system (CNS) as both
spherical and discoidal lipoprotein complexes (4) and is
strongly expressed in the choroid plexus (5, 6). Astrocytes are
thought to be the primary source of apoE in the brain, although
microglia and neurons also contribute to the apoE CNS pool
under certain circumstances (4, 7–9). Although there are several postulated pathways whereby apoE may affect synaptic
plasticity, axon guidance, neuron survival, A␤ homeostasis, and
microtubule stability, the exact pathways by which apoE isoforms influence AD remain to be fully resolved (10).
Previous studies indicate that lipidated apoE promotes the
extracellular degradation of A␤ by insulin-degrading enzyme,
targets A␤ for intracellular degradation in microglia, and facilitates A␤ clearance from the CNS via low-density lipoprotein
receptor–related protein-1 (LRP1) (11). It has also been
reported that apoE may compete with A␤ for interaction with
6

The abbreviations used are: apoE, apolipoprotein E; A␤, amyloid-␤ peptide;
AD, Alzheimer’s disease; AEBSF, 4-(2-aminoethyl)benzenesulfonyl fluoride
hydrochloride; ATRA, all-trans-retinoic acid; BCA, bicinchoninic acid; CNS,
central nervous system; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HBAI, HtrA1 boronic acid inhibitor; HtrA1, high-temperature requirement serine peptidase A1; LDL, low-density lipoprotein; LRP1, low-density
lipoprotein receptor-related protein-1; NMDase, neuraminidase; PSD95,
post-synaptic density protein 95; SMI32, non-phosphorylated neurofilament heavy chain marker; ANOVA, analysis of variance; r-apoE, recombinant apoE; r-apoE 25, recombinant apoE 25-kDa peptide; PIM, protease
inhibitor mixture.
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Apolipoprotein-E (apoE) is a glycoprotein highly expressed in
the brain, where it appears to play a role in lipid transport,
␤-amyloid clearance, and neuronal signaling. ApoE proteolytic
fragments are also present in the brain, but the enzymes responsible for apoE fragmentation are unknown, and the biological
activity of specific apoE fragments remains to be determined.
Here we utilized SK-N-SH neuroblastoma cells differentiated
into neurons with all-trans-retinoic acid (ATRA) to study extracellular apoE proteolysis. ApoE fragments were detectable in
culture supernatants after 3 days, and their levels were increased
for up to 9 days in the presence of ATRA. The concentration of
apoE fragments was positively correlated with levels of the neuronal maturation markers (PSD95 and SMI32). The most abundant apoE fragments were 25- and 28-kDa N-terminal fragments that both contained sialylated glycosylation and bound to
heparin. We detected apoE fragments only in the extracellular
milieu and not in cell lysates, suggesting that an extracellular
protease contributes to apoE fragmentation. Of note, siRNAmediated knockdown of high-temperature requirement serine
peptidase A1 (HtrA1) and a specific HtrA1 inhibitor reduced
apoE 25-kDa fragment formation by 41 and 86%, respectively.
Recombinant 25-kDa fragment apoE and full-length apoE both
stimulated neuritogenesis in vitro, increasing neuroblastoma
neurite growth by more than 2-fold over a 6-day period. This
study provides a cellular model for assessing apoE proteolysis,
indicates that HtrA1 regulates apoE 25-kDa fragment formation
under physiological conditions, and reveals a new neurotrophic
function for the apoE 25-kDa fragment.

ApoE 25-kDa peptide formation and function

Results
The SK-N-SH neuroblastoma cell line is an established in
vitro model for human neurobiology studies. Chronic treatment of SK-N-SH cells with all-trans-retinoic acid (ATRA)
induces a post-mitotic neuronal phenotype with cell monolay-
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Figure 1. ATRA induces the production of apoE and apoE fragments by
SK-N-SH cells. SK-N-SH cells were cultured for 3, 6, or 9 days in the presence
of 10 M ATRA, and the cell culture supernatants were collected and analyzed
for apoE by Western blotting. Control (Con) medium from the 3-day cell cultures was analyzed for comparison. Full-length apoE and the major apoE fragments identified by Western blotting are illustrated (A). Quantitative assessment of the full-length apoE (35 kDa) and apoE fragments at 30, 28, and 25
kDa indicate a significant time-dependent increase in all apoE species (B).
Data shown in B are derived from one experiment performed in triplicate that
is representative of three independently performed experiments. The histogram bars indicate mean values, and error bars indicate S.D. Values in B are
relative optical density measurements where the 3-day control sample is
defined as 1.0. *, p ⬍ 0.05; †, p ⬍ 0.01; ‡, p ⬍ 0.0001, compared with the
control (C) condition; one-way ANOVA with Tukey’s post hoc analysis.

ers containing a dense neurite network (23, 24). We examined
the secretion of apoE from SK-N-SH cells and the possible
influence of ATRA-mediated neuronal differentiation. Under
standard culture conditions, apoE was clearly detected in cellconditioned medium (Fig. 1A). Although the majority of apoE
(⬃80%) was present as full-length apoE, after 3 days in culture,
small amounts of apoE fragments were also detected (Fig. 1).
Treatment with ATRA time-dependently induced the production of apoE and also strongly increased the production of apoE
fragments. Analysis of the apoE size distribution profiles indicated that apoE fragments at 25 and 28 kDa were produced at
high levels with ATRA treatment (Fig. 1). After 9 days of ATRA
treatment, the levels of the dominant apoE 28- and 25-kDa
fragments were increased by ⬃30% and 6-fold, respectively
(Fig. 1B). There was very little change in the formation of apoE
fragments by cells that were cultured for up to 9 days in the
absence of ATRA (Fig. S1). In addition, examination of the fulllength Western blots indicated that small amounts of apoE
fragment at 30 kDa were detectable, and traces of fragments at
a mass ⬍ 25 kDa (i.e. at ⬃21, ⬃15, and ⬃12 kDa) were also
detectable in the cell culture supernatants (Fig. S2).
To assess the temporal association of apoE production with
the development of the SK-N-SH neuronal phenotype, we analyzed cell lysates for apoE and for markers of synapse formation
(PSD95) and neurite formation (SMI32). As expected, ATRA
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LRP1 (12) and that apoE directly regulates neuronal A␤ production in an isoform-dependent manner (13). A complete
understanding of the mechanisms by which apoE regulates AD
risk therefore remains an unresolved question.
We reported previously that apoE is proteolytically cleaved
in the human brain (hippocampus, frontal cortex, and cerebellum, both gray and white matter) and that proteolytic processing of apoE3 generates a predominant stable ⬃25-kDa fragment (14). The apoE 25-kDa fragment was not recognized by an
apoE C-terminal antibody, and, based on the predicted sensitivity of the hinge region to proteolysis, we proposed that the
apoE 25-kDa fragment represents the N-terminal four-helix
bundle that contains the LDL receptor binding domain (14).
Several other groups also detected apoE fragments in the
human brain, some of which associate with neurofibrillary tangles and amyloid plaques (15–19). As it is possible that apoE
fragments, particularly the stable 25-kDa fragment (14), may
possess biological activity, it is important to understand the
processes that contribute to the formation of apoE fragments
under physiological conditions.
As mentioned above, astrocytes are the main source of apoE
in the CNS under normal physiological conditions. However,
the cell types responsible for the generation of the apoE 25-kDa
fragment are unknown. Previous data suggest that a neuronal
chymotrypsin-like protease or aspartic protease may be
involved in apoE proteolytic fragmentation (19, 20). Either
endogenous neuronal apoE or endocytosed apoE may be processed in the neuron and (re-)secreted as apoE proteolytic fragments. Of potential relevance, apoE re-secretion pathways have
been described, at least in cells from peripheral tissues (21). It
may also be possible that neurons secrete apoE along with a
protease that together result in extracellular apoE fragmentation or that apoE that is normally constitutively secreted by
astrocytes (or microglia) is cleaved by a secreted neuronal protease. Consistent with the latter idea, rat hippocampal neurons
secrete a serine protease that generates apoE proteolytic fragments with a very similar Mr profile to the fragments seen in
human post-mortem brain samples (9). Although the identity
of the secreted enzyme responsible for the production of apoE
proteolytic fragments by rat hippocampal neurons was not
identified (9), a serine protease, high-temperature requirement
serine peptidase A1 (HtrA1) has recently been shown to cleave
recombinant apoE into fragments, including a predominant
N-terminal apoE 25-kDa fragment (22), which again is remarkably similar to the apoE fragmentation pattern seen in human
post-mortem brain samples (9, 14).
In the present study, we examined apoE proteolytic fragmentation using the human SK-N-SH neuroblastoma cell line. This
study provides a cellular model to assess apoE proteolysis,
shows that HtrA1 regulates apoE 25-kDa fragment formation
under physiological conditions, and reveals a new neurotrophic
function for the apoE 25-kDa fragment.

ApoE 25-kDa peptide formation and function

shown (D). Quantitative data shown are derived from one experiment performed in triplicate representative of three independently performed experiments. The histogram bars represent the mean value, and the error bars represent S.D. values. *, p ⬍ 0.05; †, p ⬍ 0.01; ‡, p ⬍ 0.0001 compared with the
control (C) condition; one-way ANOVA with Tukey’s post hoc analysis. Scale
bars in D, ⫽ 25 m.
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Figure 2. Regulation of SK-N-SH cellular apoE and synaptic marker levels
by ATRA. SK-N-SH cells were cultured for 3, 6, or 9 days in the presence of 10
M ATRA. The cell lysates were analyzed for apoE, non-phosphorylated neurofilament H (SMI32), PSD95, and the housekeeper proteins tubulin and
GAPDH by Western blotting (A). Lysates from the 3-day control (Con) cell
cultures were analyzed for comparison. Quantitative assessment of the fulllength apoE (35 kDa) and the neurofilament and synaptic marker proteins
(SMI32 and PSD95) indicate a significant time-dependent increase compared
with the housekeeper proteins (B and C). Data in B and C are relative optical
density measurements, and the 3-day control sample is defined as 1.0. Phasecontrast images of the 3-day control and 9-day ATRA-treated (ATRA) cells are

strongly increased PSD95 and SMI32 levels over the 9-day
experiment (Fig. 2A). Phase-contrast images confirmed that the
changes in these differentiation markers were associated with
the development of a more neuronal phenotype (Fig. 2D). Consistent with the data in Fig. 1, cellular apoE levels were also
time-dependently up-regulated by ATRA treatment (Fig. 2B).
Intracellular apoE was detected as a doublet or triplet band that
is consistent with previous studies of intracellular apoE maturation and glycosylation (25). Importantly, no apoE fragmentation products were detected in cell lysates at any of the time
points examined, in either the presence or absence of ATRA
(Fig. S3). These data indicate that apoE is up-regulated in concert with ATRA-induced neuronal differentiation and suggest
that apoE proteolytic fragmentation may only occur in the
extracellular compartment.
Based on our previous results from post-mortem human
brain tissue (14), we predicted that the apoE 25–28-kDa fragments generated by ATRA-treated SK-N-SH cells may be
N-terminal fragments. A protease-susceptible hinge domain
separates the apoE N-terminal and C-terminal domains (Fig.
3A), and this is predicted to contain a number of enzyme cut
sites. Using apoE N terminus–specific and C terminus–specific
antibodies (recognizing residues 141–160 and 285–299,
respectively), we confirmed that the two quantitatively dominant apoE fragments at 28 and 25 kDa were N-terminal fragments (Fig. 3B). Furthermore, the apoE N-terminal fragments
both strongly bound to heparin (Fig. 3C), consistent with the
known N-terminal heparin-binding domain comprising residues 143–146 (26). These apoE fragments were also reduced
slightly in Mr after treatment with neuraminidase, consistent
with cleavage of terminal sialic acid residues from the O-linked
glycan at Thr194 (Fig. 3D). The calculated molecular mass of the
apoE N-terminal peptide, including Thr194, is 22,373 Da.
Although the degree of CNS apoE sialylation is variable (25),
using the mass of one of the most abundant apoE O-glycan
species at Thr194 (i.e. HexNAc-Hex(NeuAc)2) of 947 Da (27),
the minimum predicted mass of a glycosylated apoE N-terminal fragment (residues 1–194) would therefore be ⬃23.3 kDa
(i.e. predicted to migrate to a position just below the 25-kDa
PAGE marker protein, which is where the apoE 25-kDa fragment is detected) (Fig. 3B).
To gain mechanistic information related to the extracellular
formation of apoE N-terminal fragments, a selection of protease inhibitors was added to 9-day ATRA-differentiated SKN-SH cell cultures for a period of 24 h. It is important to note
that the degree of apoE fragmentation detected over the 24-h
period used in these experiments is much lower than observed
with 3-day culture periods (compare Fig. 4 (A and D) with Fig.
1A). The 24-h period was used to minimize nonspecific effects
that the protease inhibitors may have on cellular metabolism.
The presence of a broad-spectrum protease inhibitor mixture
inhibited the formation of the major apoE N-terminal frag-

ApoE 25-kDa peptide formation and function
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heparin binding using heparin-affinity chromatography and Western blotting. Full-length apoE and the apoE 25- and 28-kDa fragments were strongly
bound to the heparin column and eluted with 0.5 M NaCl (C). The cell culture
supernatants were also assessed for the presence of sialylated glycans using
neuraminidase treatment and Western blotting. The dashed lines indicate the
shift in full-length apoE and apoE fragment size due to desialylation. Fulllength apoE and the apoE 25- and 28-kDa fragments all migrated further in
the blot after neuraminidase treatment, thereby removal of sialic acid (D).
Data are derived from one experiment representative of at least two independently performed experiments.
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Figure 3. Characterization of apoE fragments. A schematic overview of
apoE3 domain structure is shown (A). The LDL receptor-binding region
(Receptor), heparin-binding region (Heparin), O-linked glycosylation site
(O-Glycan), and lipid-binding domains (Lipid) are depicted. The Cys112 and
Arg158 residues of apoE3 indicate the variable positions responsible for the
three major apoE isoforms (A). SK-N-SH cells were cultured for 9 days in the
presence of 10 M ATRA, and the cell culture supernatants were collected and
analyzed for apoE by Western blotting using a goat polyclonal antibody
raised against full-length apoE (Pan), as well as monoclonal antibodies specific for the apoE N terminus (N-term) and C terminus (C-term) (D6E10 and E8,
respectively, recognizing epitopes comprising amino acid residues 141–160
and 285–299, respectively, as shown in A). Full-length apoE and the apoE 25and 28-kDa fragments were detected by the full-length apoE and apoE N
terminus antibodies, whereas only full-length apoE was identified by the
apoE C terminus antibody (B). The cell culture supernatants were assessed for

ments at 25 kDa by 75% (p ⫽ 0.0002) and at 28 kDa by 75% (p ⫽
0.0007) (Fig. 4, A and C, respectively), whereas the levels of
full-length secreted or intracellular apoE were unaffected (Fig.
4, A–C). Similarly, the serine protease inhibitor 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF) inhibited
the formation of the major apoE N-terminal fragments at 25
kDa by 81% (p ⫽ 0.0134) and at 28 kDa by 87% (p ⫽ 0.0033) (Fig.
4, D and F), whereas the levels of full-length apoE were unaffected (Fig. 4, D–F). These results suggest that an extracellular
serine protease contributes to the production of apoE N-terminal fragments. These results are consistent with a previous
study using rat hippocampal neuron-conditioned medium and
exogenously added apoE in the presence or absence of a protease inhibitor mixture or the serine protease inhibitor phenylmethylsulfonyl fluoride (9).
In a recent study using recombinant proteins, the serine protease HtrA1 was shown to produce apoE N-terminal fragments
in an apoE isoform– dependent manner (22). Indeed, the
HtrA1-mediated proteolysis of recombinant apoE3 produced a
major apoE N-terminal fragment of ⬃25 kDa that was shown to
encompass amino acid residues 1–195 (22). Intriguingly, in
these studies, larger fragments of apoE (e.g. 28 kDa) were not
generated (22). Furthermore, the apoE 25-kDa fragment was
more rapidly degraded further by HtrA1 to smaller fragments
when the apoE4 recombinant protein was assessed, as compared with apoE3 recombinant protein (22). This result is strikingly similar to what has been observed in human post-mortem
brain tissues, in which carriers of the APOE⑀3/3 genotype had
increased levels of the apoE 25-kDa fragment as compared with
APOE⑀4/4 carriers (14).
To test for a possible contribution of HtrA1 in the SK-N-SH–
mediated production of the apoE N-terminal 25-kDa fragment,
we first assessed the expression of HtrA1 in SK-N-SH cells.
Quantitative RT-PCR indicated that HTRA1 mRNA was present in SK-N-SH cells under standard culture conditions and
that levels were time-dependently increased by 7.4-fold (p ⫽
0.0003) after 9 days in culture in the presence of ATRA (Fig. S4).
This was also confirmed using standard semiquantitative PCR,
where a 3.8-fold (p ⫽ 0.0003) up-regulation of HTRA1 mRNA
level was observed (Fig. S5A). We also detected extracellular
HtrA1 protein and found that the levels were significantly
increased after 9 days in culture with ATRA treatment (Fig. S5).
The HtrA1 Western blots identified two HtrA1 species at ⬃50
and 38 kDa (Fig. S5D). This is consistent with previous studies
that have shown that the 38 kDa band is an autocatalytic product of the full-length 50-kDa HtrA1 protein (28). Overall,
SK-N-SH–secreted HtrA1 protein levels were increased by 2.1fold (p ⫽ 0.0002) after 9 days in culture with ATRA (Fig. S5B).

ApoE 25-kDa peptide formation and function

To assess the role of HtrA1 in the SK-N-SH–mediated production of the apoE N-terminal 25-kDa fragment, we used an
siRNA approach. HTRA1 mRNA levels were reduced by ⬎90%
relative to both vehicle control and scrambled siRNA (both p ⬍
0.0001) following transfection of the cells with HTRA1 siRNA
(Fig. 5, A and B). Similarly, extracellular HtrA1 protein levels
were reduced by 91% (p ⬍ 0.0001) by HTRA1 siRNA when
assessed at day 9 (Fig. 5, C and D). As HtrA1 regulates the
growth and differentiation of neurons and other cell types (29 –
31), we quantified cell confluence using live cell imaging over
time and also measured cellular protein levels at day 9. The
siRNA-mediated knockdown of HTRA1 reduced cell growth
(confluence) and total cell protein by 37 and 39% (p ⬍ 0.01),
respectively (Fig. S6). We assumed that this decrease in cell
growth and consequently cell protein levels would also further
decrease apparent HtrA1 levels; therefore, the values for HtrA1
protein level in the HTRA1 siRNA condition illustrated in Fig.

5D have been increased by 39% to compensate for the reduction
in cell numbers and total cell protein under this condition.
We then measured the amount of apoE 25- and 28-kDa fragments (as a proportion of full-length apoE) under the day 9
siRNA treatment conditions. The apoE Western blots shown in
Fig. 5E were loaded with equal amounts of full-length apoE in
each lane to compare the fragmentation. The data demonstrate
that HTRA1 siRNA selectively reduced the apoE 25-kDa fragment concentration by 41% (p ⬍ 0.0001) in the medium,
whereas the levels of the apoE 28-kDa fragment were unaffected (Fig. 5, E and F), thus indicating that HtrA1 specifically
regulates the production of the apoE 25-kDa fragment under
physiological conditions.
Intriguingly, we detected a 25% (p ⫽ 0.01) increase in HTRA1
mRNA in the scrambled siRNA condition (Fig. 5B), and this
was associated with a similar modest 25% (p ⫽ 0.02) increase in
apoE 25-kDa fragment concentration (Fig. 5F). Although this
J. Biol. Chem. (2018) 293(11) 4071–4084
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Figure 4. Inhibition of apoE proteolytic fragmentation by protease inhibitors. SK-N-SH cells were cultured for 9 days in the presence of 10 M ATRA. The
culture medium was then replaced with fresh medium alone (Con) or with fresh medium containing either a broad-spectrum PIM or the serine protease
inhibitor AEBSF and cultured for a further 24-h period. The addition of PIM inhibited the formation of apoE fragments in the supernatant (S/N) (A). The addition
of PIM had no impact on cellular apoE levels (B). A similar result was observed when AEBSF was used to treat the cells (D and E). Quantitative assessment of the
full-length apoE (35 kDa) and apoE fragments at 28 and 25 kDa indicates a significant inhibition of apoE fragment formation in the presence of either PIM (C;
light gray bars) or AEBSF (F; light gray bars)). Data in C and F are relative optical density measurements, in which the vehicle control (DMSO 1:1000) sample (dark
gray bars) is defined as 1.0. Data shown are derived from one experiment performed in triplicate and representative of three independently performed
experiments. The histogram bars represent mean values, and the error bars represent S.D. *, p ⬍ 0.05; †, p ⬍ 0.01 compared with the respective control for each
fragment; two-tailed t test.

ApoE 25-kDa peptide formation and function

was unexpected, as the scrambled siRNA was designed by the
manufacturer to be a non-biologically active control, it is nonetheless noteworthy that increased HtrA1 levels were associated
with an increased apoE 25-kDa fragment concentration.
As the production of the apoE 25-kDa fragment was only
partially, albeit highly significantly, inhibited (⬃40%) by the
HTRA1 siRNA, and also because this treatment had an impact
on cell growth (Fig. S6), we next assessed the role of HtrA1 in
apoE 25-kDa fragment formation using HtrA1 boronic acid
inhibitor (HBAI; Fig. 6A), as a highly specific HtrA1 inhibitor
(22). Based on previous studies (22), we used HBAI at a concentration of 1 M. When 9-day ATRA-differentiated SK-N-SH

4076 J. Biol. Chem. (2018) 293(11) 4071–4084

cells were treated with HBAI, the formation of the apoE N-terminal 25-kDa fragment was inhibited by 86% (p ⫽ 0.0004),
whereas the levels of either secreted or cellular full-length apoE
were unaffected (Fig. 6, B–D). These data confirm that HtrA1
contributes to the proteolytic formation of apoE 25-kDa fragment under physiological conditions.
A previous study demonstrated that recombinant HtrA1
cleaves recombinant apoE to generate a quantitatively major
25-kDa fragment, which was determined by peptide mapping
mass spectrometry to encompass apoE amino acid residues
1–195 (22). Based on the fact that this peptide encompasses the
apoE N-terminal four-helix bundle and therefore expresses the
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Figure 5. Suppression of HtrA1 by siRNA reduces SK-N-SH cellular apoE proteolytic fragmentation. SK-N-SH cells were cultured for up to 9 days in the
presence of siRNA targeting HTRA1 (siRNA), vehicle control (Con), or a scrambled siRNA (Scr), and the level of HTRA1 mRNA was determined by quantitative
real-time PCR (A). Relative amounts of HTRA1 mRNA and HtrA1 protein were determined by quantitative real-time PCR and Western blotting after 9 days of
exposure to siRNA targeting HTRA1 (siRNA), vehicle control (Con), or a scrambled siRNA (Scr) as shown in the histograms (B and D). A representative Western blot
of extracellular HtrA1 present in the growth medium collected at day 9 (medium exposed to cells for 72 h, from day 6 to day 9) is shown (C). The same medium
was also assessed for apoE fragmentation by Western blotting (E and F). The data in A are derived from one experiment performed in duplicate. Data in B and
F are derived from three independently performed experiments performed in either triplicate or quadruplicate. Data in D are derived from one experiment
(blot shown in C) representative of three experiments independently performed in either triplicate or quadruplicate. The histogram bars represent mean
values, and the error bars represent S.D., except in A, where the error bars represent the range. *, p ⬍ 0.05; ‡, p ⬍ 0.0001 compared with the control (Con)
condition; one-way ANOVA with Tukey’s post hoc analysis.

ApoE 25-kDa peptide formation and function

(DMSO (1:1,000), dark gray bars) are defined as 1.0. Data in D are derived from
one experiment performed in triplicate (Western blots shown in B and C) and
are representative of three independently performed experiments. The histogram bars represent mean values, and the error bars represent S.D. †, p ⬍
0.01 compared with the respective control for each fragment; two-tailed t
test.
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Figure 6. HtrA1 inhibitor reduces SK-N-SH cellular apoE proteolytic fragmentation. The structure of HBAI is shown (A). SK-N-SH cells were cultured
for 9 days in the presence of 10 M ATRA. The culture medium was then
replaced with fresh medium alone (Con) or with fresh medium containing
either HBAI (1 M) or vehicle control and cultured for a further 24-h period.
The addition of HBAI inhibited the formation of the apoE 25-kDa fragment in
the supernatant (S/N) (B). HBAI addition had no impact on cellular apoE levels
(C). Quantitative assessments of the full-length apoE (35 kDa) and apoE fragments at 28 and 25 kDa indicate a significant inhibition of apoE 25-kDa fragment formation in the presence of HBAI (light gray bars; D). Data in D are
relative optical density measurements in which the vehicle control samples

LDL receptor– binding region (32) and that apoE is well-established to promote neurite outgrowth via interaction with LDL
receptor family members (33–37), we next assessed the impact
that the recombinant apoE 25-kDa peptide (r-apoE 25; amino
acid residues 1–195) has on neuritogenesis in vitro. In these
experiments, we used the SH-SY5Y cell line. This cell line was
chosen, as it is a subclone of the SK-N-SH line that does not
produce detectable apoE and does not produce the high degree
of neurite growth that is observed with ATRA-treated SKN-SH neurons (23). Based on previous studies (35–37) and our
own pilot experiments, we used apoE concentrations of 5 and
20 g/ml.
In the absence of r-apoE and r-apoE 25, SH-SY5Y cells developed a neuronal phenotype after 6 days, with clearly identifiable
but relatively short neurites (Fig. 7). Neurite length data were
collected in units of mm of total neurites detected/mm2. For the
control conditions (Fig. 7B, Con), including 0-, 3-, and 6-day
culture, the neurite length value was 1.46 ⫾ 0.09 mm/mm2
(mean ⫾ S.E., n ⫽ 30) and remained unchanged over the 6-day
period. Under these conditions where ATRA and low serum
levels are present (see “Experimental procedures”), the addition
of either r-apoE or r-apoE 25 did not have a major impact on cell
growth, with confluence levels at a very similar level at day 6
(Fig. 7). However, in agreement with previous studies (35, 37),
r-apoE did dose-dependently promote neuritogenesis, with
neurite growth increased by 2.4-fold (p ⬍ 0.0001) after 6 days of
supplementation at 20 g/ml r-apoE concentration (Fig. 7B).
Similarly, the addition of 20 g/ml r-apoE 25 also strongly promoted neuritogenesis, with neurite growth increased by 2.2fold (p ⬍ 0.0001) after 6 days (Fig. 7B). At the lower dose of 5
g/ml, r-apoE also significantly promoted neuritogenesis with
neurite growth increased by 2.1-fold (p ⬍ 0.0001) after 6 days,
whereas a non-significant trend for increased neurite growth
was observed at the lower dose of r-apoE 25 (Fig. 7B). Overall
viability was reduced by 19% (p ⫽ 0.0007) after 6 days in the
presence of 20 g/ml r-apoE but was not affected in the other
conditions tested (Fig. 7C). The cell culture medium was also
collected when the cells were harvested at day 6 (i.e. the
medium was present on the cells for 72 h, from day 3 to day 6)
and assessed for apoE by Western blotting. As predicted, the
medium that was not supplemented with either form of recombinant apoE did not contain detectable apoE (Fig. S7). Interestingly, full-length r-apoE was partly proteolyzed over the 72-h
incubation period to generate the apoE 25-kDa fragment (Fig.
S7B). In the case of r-apoE 25, no proteolysis was observed (Fig.
7B). A quantitatively minor band (accounting for ⬃10% of total
r-apoE 25) was present in the r-apoE 25 before addition to the
cells, and the level of this minor fragment did not change during
the 72-h incubation (Fig. 7B). Overall, these data reveal that the
apoE 25-kDa fragment that is derived from HtrA1-mediated
proteolysis is a relatively stable fragment that promotes neuri-
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togenesis to a similar degree as reported previously for fulllength apoE.

Discussion
Herein, we describe a cell culture system that recapitulates
the physiologically relevant process of apoE proteolytic fragmentation, a process known to occur in the human brain. Building on recent studies showing that the proteolytic fragmentation of exogenous apoE involves an extracellular neuronal
serine protease (9) and that recombinant HtrA1 generates apoE
fragments, particularly a major 25-kDa fragment (22) that is
very similar to the major apoE fragment detected in the human
brain (14), we showed here, using siRNA knockdown of HtrA1
and a highly specific HtrA1 inhibitor, that endogenous apoE is
selectively cleaved by endogenous HtrA1 and that the process is
linked to neuronal differentiation state. Consistent with our
findings, previous studies have also shown that HtrA1 expression is tightly linked with neuronal development both in vitro
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Figure 7. Recombinant apoE 25-kDa fragment stimulates SH-SY5Y neuritogenesis. Full-length recombinant apoE and apoE 25 (1–195 fragment)
were added to SH-SY5Y cells at concentrations of 5 and 20 g/ml 24 h after
plating (day 0), with medium change at day 3 day and final analysis at day 6.
Confluence (A) and neurite length (B) were assessed at t ⫽ 0 and then every 3
days using an IncuCyte Zoom live cell analysis system. Cell viability was measured at day 6 (C). All data are expressed relative to the respective day 0
control (Con) condition, which is defined as 1.0. Data are derived from two
independent experiments performed in quintuplicate. The histogram bars
represent mean values, and the error bars represent S.D. †, p ⬍ 0.01; ‡, p ⬍
0.0001 compared with the respective day 0 control for each condition (A and
B) or †, p ⬍ 0.01 compared with the control (Con) condition; one-way ANOVA
with Tukey’s post hoc analysis. Arrows, neurites (D). Scale bars in D, 100 m.

and in vivo (29, 30) and that HtrA1 expression levels are positively correlated with PSD95 levels during neuronal differentiation (30). In addition, loss of HtrA1-mediated proteolysis of
TGF-␤ was shown to directly prevent neuronal differentiation
(30). Intriguingly, similar to our current findings with SK-N-SH
neurons, ATRA was reported to induce HtrA1 expression associated with osteogenic differentiation of adipose-derived stromal cells (38). In this case, siRNA-induced knockdown of
HtrA1 prevented ATRA-mediated stromal cell osteogenesis
(38). These findings raise the possibility that both HtrA1 activity and apoE-mediated signaling may act together to regulate
neuronal differentiation.
To explore the relationship between HtrA1 expression and
the biological activity of the apoE 25-kDa fragment, we generated a recombinant apoE fragment (spanning residues 1–195)
that corresponds to the main apoE fragment generated by
HtrA1. Our data indicate potent neuritogenic activity of
the apoE 25-kDa fragment that is very similar to that of fulllength apoE. There is previous evidence that apoE fragments
(and apoE-mimetic peptides) are biologically active, as they
regulate neuronal signaling (39, 40) and control either neurodegenerative or neuroprotective pathways and anti-inflammatory pathways, depending on the fragments analyzed (15, 18,
41–54). Some of these previous reports focused on a potentially
toxic apoE C-terminal truncated 30-kDa fragment and other
shorter thrombolytic and synthetic fragments, which were suggested to be present in the “insoluble fractions” of human AD
brain homogenates. In our own studies, we detected a stable
apoE 25-kDa fragment that was present in the Tris-soluble fractions of human brain homogenates (14). Because the concentration of this soluble apoE fragment was strongly associated
with the apoE3 isoform, we speculated that it may provide a
protective function in the brain (14, 55). This is consistent with
the findings of our current work, as the stimulation of neuritogenesis by the apoE 25-kDa fragment would also be predicted to
represent a protective function in vivo.
It is important to consider the concentrations of apoE
25-kDa fragment and full-length apoE used in our current study
(5 and 20 g/ml) in relation to the levels detected in human
tissues. Human CSF and plasma contain apoE at concentrations of ⬃10 and 50 g/ml, respectively (56, 57). Levels of soluble apoE in the human frontal cortex, temporal cortex, and
cerebellum are reported to be 95, 122, and 48 g/g protein,
respectively (58). Based on a total protein content of ⬃8 –10%
for human brain tissues (59), it is conceivable that total adult
brain apoE would be present at low g/g wet tissue weight levels
(i.e. similar to the concentrations we have used here). It is also
noteworthy that as a predominantly secreted protein, extracellular apoE levels in interstitial fluid may be different from total
tissue levels derived from the soluble fraction of homogenates.
Human brain apoE concentration also varies throughout life;
indeed, neonatal brain apoE levels are twice the level found in
adults (60), presumably due to the neurotrophic role of apoE
during brain development. Soluble brain apoE concentrations
are therefore likely to fluctuate, depending on several physiological parameters. It appears that, similar to previous studies
focusing on apoE biological functions (35–37), the low g/ml
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HtrA1 is widely expressed in adult human tissues, including
the brain, where it has been localized to neurons, astrocytes,
oligodendrocytes, and microglia (74). In addition, HtrA1
expression is regulated spatially and temporally in the developing mouse brain (75) and is known to control neuronal maturation and developmental survival via regulation of the TGF-␤
signaling pathway by eliciting TGF-␤ proteolytic cleavage (30).
Indeed, HtrA1 is well known to modulate a variety of signaling
pathways through proteolytic cleavage (or chaperone-like
sequestering) of regulatory proteins (31), which would be in line
with a biological signaling function for the apoE 25-kDa fragment. Based on data from our studies and many other laboratories, it is clear that several proteolytic fragments of apoE in
addition to the 25-kDa species are generated both in vitro and
in vivo, and it is possible that different apoE fragments may have
varying biological functions. It is also probable that these other
fragments are generated by one or more additional serine proteases, as they have not been detected in studies that focused on
proteolytic fragment mapping of digests resulting from incubation of recombinant apoE with recombinant HtrA1 (22).
The role that HtrA1-mediated proteolysis of apoE could play
in AD is also not fully established. Previous studies have shown
that HtrA1 cleaves Tau and the amyloid precursor protein (76 –
78), which is predicted to promote protection in the AD context. Furthermore, HtrA1 levels and activity are increased in
response to the development of AD pathology (77). It was also
recently established that HtrA1 degrades apoE4 more rapidly
than apoE3 (22), which may contribute to the overall reduced
levels of apoE4 detected in AD brain tissues as compared with
apoE3. It is currently unclear how HtrA1 differentially cleaves
apoE3 and apoE4 to generate a different fragmentation pattern.
The HtrA1 cut site generating the apoE 25-kDa fragment
(encompassing amino acids 1–195) was defined using mass
spectrometry peptide mapping (22). HtrA1 cuts after apoE
Val194, which is typical of an elastase-like serine protease activity. Although HtrA1 activity is thought to be more like a trypsin-like serine protease, regulation via substrate interaction
with a PDZ domain may influence the enzyme’s protease activity (79, 80). Of potential significance, binding of substrate
C-terminal or internal hydrophobic stretches of amino acids
(or protein-associated lipid) to the HtrA1 PDZ can modulate
protease activity (79, 80), and this is thought to contribute to
the processing of unfolded proteins by HtrA1. Intriguingly, the
apoE4 N-terminal four-helix bundle is known to be less stable
than apoE3 (81). Indeed, previous data indicate that apoE4 may
form a molten globule-like state in which the four-helix bundle
is partially opened and elongated, thereby exposing the hydrophobic core of the protein (81). This may contribute to the
differential processing of apoE3 and apoE4 by HtrA1. Elucidation of the precise structural details of HtrA1-mediated apoE
isoform–specific proteolysis clearly requires further study.
Nonetheless, there are several plausible routes by which HtrA1
could regulate AD development, and these now appear to
include impacts on apoE metabolism.
In conclusion, our study provides a cellular model to assess
apoE proteolysis, shows that HtrA1 regulates apoE 25-kDa formation under physiological conditions, and reveals a new neurotrophic function for the apoE 25-kDa fragment.
J. Biol. Chem. (2018) 293(11) 4071–4084
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apoE levels that we have used are likely to be physiologically
relevant.
The level of the apoE 25-kDa fragment present in the human
brain has not been accurately quantified. However, in a previous Western blot analysis of adult human frontal cortex, temporal cortex, and occipital cortex, we found that the soluble
apoE 25-kDa fragment accounted for 20% of total apoE (14).
This is very similar to the relative amounts of apoE 25-kDa
fragment detected in SK-N-SH neuron culture medium after 9
days of ATRA treatment in the present study. Interestingly, our
previous study showed that the concentration of soluble cortical apoE 25-kDa fragment present in APOE⑀3 homozygotes
was 3-fold higher than in APOE⑀4 homozygotes (14). It is possible that these differences in neurotrophic apoE 25-kDa fragment concentration over a lifetime may contribute to the
increased AD risk associated with the APOE⑀4 genotype. We
hasten to add, however, that further work will clearly be
required to investigate the potential neurotrophic function of
the apoE 25-kDa fragment in vivo.
Based on the knowledge that apoE provides neurotrophic
support via its interactions with LDL receptor family members
(1, 7, 34, 61, 62), and that the apoE 25-kDa fragment we have
identified is stable in vitro and in vivo, it is plausible that this
fragment may also promote neuritogenic effects via interaction
with LDL receptor family members, as has been demonstrated
in previous studies with full-length apoE under numerous
experimental settings (35–37, 63). Evidence that the apoE
N-terminal fragment interacts with LDL receptor family members is provided by previous studies that have shown the apoE
N-terminal domain (the 22-kDa fragment, residues 1–183,
associated with dimyristoyl-phosphocholine) is recognized by
the LDL receptor (64, 65). Of potential relevance, the injection
of apoE N-terminal fragment (residues 1–191) into rabbits
indicated a clearance rate from the circulation that is consistent
with a receptor-mediated process, for example, via hepatic
LRP1 (66), although the fragment was not associated with
lipoprotein particles (67). In addition, apoE-derived mimetic
peptides that span the LDL receptor– binding region have
been used successfully as neuroprotective agents in mice (49,
50, 68, 69).
We also speculate that the apoE 25-kDa fragment may represent a particularly potent neuritogenic agent in vivo, as other
functions of full-length apoE that are driven primarily by
regions in the C-terminal domain (such as permitting lipoprotein interaction (67, 70), promoting self-aggregation (67, 70),
and facilitating A␤ binding and clearance (17)) would be
removed or reduced in the apoE 25-kDa fragment, thereby
selectively promoting apoE signaling functions via interaction
with LDL receptor family members. Previous studies have
shown that ApoE knockout mice have cognitive deficits that are
more pronounced in females and are exacerbated by age in
association with blood-brain barrier dysfunction (71–73).
Based on the approach of targeted replacement with either fulllength or truncated forms of human apoE in ApoE⫺/⫺ mice (19,
71, 73), in the future, it would be interesting to use a similar
approach to test for the potential protective effect of the apoE
25-kDa fragment on synaptic and cognitive dysfunctions in
vivo.
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AB_477590, 1:5,000), apoE N-terminal D6E10 (Abcam catalog
no. ab1906, RRID:AB_302668, 1:1,000), apoE C-terminal (clone
E-8, Santa Cruz Biotechnology, Inc., catalog no. sc-393302,
1:200), and HtrA1 monoclonal antibody (R&D Systems catalog
no. MAB2916, RRID:AB_2122710, 1:500, used under non-reducing PAGE conditions). The membranes were washed three
times in PBS-T, and signals were detected using species-specific HRP-conjugated secondary antibodies (all from donkey,
Santa Cruz Biotechnology, Inc. (1:5,000) or Jackson ImmunoResearch Laboratories (1:5,000)), and the proteins of interest
were detected using enhanced chemiluminescence (ECL,
Amersham Biosciences or Pierce ECL Plus Western blotting
substrate, Thermo Fisher Scientific) and captured by X-ray film
or by a gel imager (GE Amersham Biosciences Imager 600).
Signal intensity was quantified using ImageJ software (W. S.
Rasband, National Institutes of Health, Bethesda, MD).
For quantification of apoE proteolytic fragments, a fixed area
was used to separately measure signal intensity from the
regions encompassing full-length apoE (⬃35 kDa) and apoE
fragments at ⬃28 and ⬃25 kDa. An adjacent blank region was
used as a background control. Relative differences between
samples were always assessed on the same blots.

Microscopy

Assessment of apoE/apoE fragment desialylation and heparin
binding

Phase-contrast images of SK-N-SH cells grown for 9 days in
12-well cell culture plates under standard culture conditions or
in the presence of 10 M ATRA were acquired using a Nikon
Eclipse 300 inverted cell culture microscope and ⫻10 objective.
Bright-field images of SH-SY5Y cells were taken using an
IncuCyte Zoom live cell analysis system with a ⫻20 objective
(Essen BioScience, Ann Arbor, MI). Confluence and neurite
length were assessed every 3 days, and images were analyzed
using the IncuCyte software.
Western blotting
SK-N-SH cell culture medium and cell lysates were collected
at the indicated times. Cell lysates were harvested in lysis buffer
(radioimmune precipitation assay lysis buffer (10 mM Tris-Cl
(pH 8.0), 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl, 1 mM phenylmethylsulfonyl
fluoirde) with PIM (1:100)) essentially as described previously
(8, 84). In brief, bicinchoninic acid (BCA) protein assays were
performed on cell lysates, and equal amounts of protein
(⬃15–50 g of protein/lane) were separated on reducing SDSpolyacrylamide gels (8, 12, or 15%, depending on the Mr of the
protein of interest) and transferred onto 0.45-m nitrocellulose
membranes at 100 V for 30 min. Membranes were Ponceaustained and scanned before blocking overnight at 22 °C for 1 h
in PBS containing 0.1% (w/v) Tween-20 (PBS-T) containing 5%
(w/v) nonfat dry milk. The membranes were then probed with
the relevant antibodies at 4 °C for 16 h to reveal the bands of
interest. Dilutions of antibodies used were as follows: apoE
(goat polyclonal Millipore catalog no. 178479, RRID:
AB_2057989, 1:10,000), SMI32 (Covance Research Products
Inc. catalog no. SMI-312R, RRID:AB_2314906, 1:2,000), PSD95
(Millipore catalog no. 04-1066, RRID:AB_1977415, 1:500),
GAPDH (rabbit polyclonal, OSG00032W, Osenses, 1:10,000),
␤-tubulin isotype III (Sigma-Aldrich catalog no. T8660, RRID:
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Where indicated, 9-day ATRA-treated cell culture supernatant samples were treated with neuraminidase (NMDase; catalog no. N3786, Sigma) to probe for sialylation on full-length
apoE and apoE fragments. Samples (0.3 ml) were mixed with an
equal volume of 1⫻ NMDase reaction buffer, and 6 l of
enzyme solution was added. Sample controls were treated using
the same buffers but without NMDase. After incubation at
37 °C for 14 h, all samples were heated at 100 °C for 5 min and
then analyzed by 15% SDS-PAGE and Western blotting for
apoE detection as described above.
The heparin-binding activity of full-length apoE and apoE
fragments was assessed using HiTrap Heparin HP columns (GE
Healthcare, Rydalmere, Australia), following the manufacturer’s instructions. In brief, the column was equilibrated with 10
ml of 100 mM sodium phosphate buffer (pH 7), and 9 ml of
9-day ATRA-treated cell culture supernatant sample was added
after the addition of 1 ml of 100 mM NaCl “load” sample. Heparin-binding proteins were then eluted by the addition of 5 ml
of 100 mM NaCl, followed by 5 ml of 500 mM NaCl. The load
sample and the eluates were then analyzed by 15% SDS-PAGE
and Western blotting for apoE detection as described above.
Quantitative real-time PCR
Analysis of mRNA expression level was carried out using
quantitative real-time PCR as previously reported (85). Cells
were rinsed twice with ice-cold PBS. Total cellular RNA was
extracted with TRIsure reagent (Bioline (Sydney, Australia),
catalog no. BIO-38022), according to the manufacturer’s
instructions. The concentration of the purified RNA was determined by recording the absorbance at 260 nm using a Nanodrop 2000 (Thermo Scientific, Wilmington, DE), and the purity
and the integrity of the isolated RNA were checked by determining the A260/A280 ratio (⬎1.8). Two g of total RNA was
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Experimental procedures
Cell culture and treatments
Cell culture media and additives were from Life Technologies (Melbourne, Australia). Human SK-N-SH and SH-SY5Y
neuroblastoma cells (American Type Culture Collection
(ATCC (Manassas, VA) catalog nos. HTB-11 and CRL-2266,
respectively)) were routinely maintained in Dulbecco’s modified Eagle’s medium/F-12 (1:1, v/v) growth medium supplemented with 5% (v/v) fetal bovine serum, 2 mM glutamine, 100
IU/ml penicillin, and 100 g/ml streptomycin. Cultures were
grown in 75-cm2 flasks at 37 °C in 5% CO2 and plated into
multiwell plates for use in experiments. Where indicated, cells
were treated with the following compounds (or appropriate
vehicle control) for the time intervals indicted in the text and
figure legends: ATRA (10 M; Sigma-Aldrich, Castle Hill, Australia), protease inhibitor mixture (PIM; catalog no. P8340,
1:1000, Sigma-Aldrich), AEBSF (1 mM, catalog no. A8456, Sigma-Aldrich), and HBAI (1 M) synthesized as described previously (22). SK-N-SH and SH-SY5Y cells were genotyped as
described previously (14) and confirmed to be homozygous for
the APOE⑀3 genotype, as previously reported (82, 83).
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HtrA1 siRNA experiments
Human HTRA1 siRNA (5⬘-GAAGUGAUUGGAAUUAACATT-3⬘; 5⬘-UGUUAAUUCCAAUCACUUCTT-3⬘) and
scrambled siRNA (5⬘-GAAAGUUGGAUCAAUAAGUTT-3⬘;
5⬘-ACUUAUUGAUCCAACUUUCTT-3⬘) were designed by
and obtained from Sigma-Aldrich and transfected into SKN-SH cells using Lipofectamine RNAiMAX (Thermo Scientific), following the manufacturer’s instructions. SK-N-SH cells
were seeded at 100,000 cells/well in a 12-well plate and cultured
under the conditions described above for 9 days. HTRA1
siRNA was transfected 24 h after the initial seeding, and
media were changed every 3 days until cells were analyzed at
day 9 for mRNA and protein expression as described above.
Total protein for the cell lysate was quantified using the
detergent-compatible Lowry method (DC Protein Assay,
Bio-Rad, Gladesville, Australia), following the manufacturer’s instructions.
Expression and purification of recombinant human apoE and
apoE 25
The APOE3 cDNA clone was kindly provided by Dr. Zhijiang
Chen (Salk Institute), and full-length apoE was generated as
described previously (22). The apoE 25 (amino acids 1–195)
coding sequence was subcloned into the pHisMAL vector with
a tobacco etch virus cleavage site between the apoE protein and
the His6-MBP for bacterial expression. The apoE 25 protein was
then expressed in Escherichia coli strain Rosetta 2 (DE3), and

the recombinant protein was isolated from bacterial lysates as
described previously (22) and incubated with tobacco etch virus
protease at 4 °C for 12 h to cleave off the His6-MBP tag. The
cleaved protein mixture was incubated with nickel-nitrilotriacetic acid resin to remove the His6-MBP tag, and the apoE 25
protein was further purified by monoQ and size-exclusion
chromatography. Eluted apoE 25– containing fractions were
pooled and concentrated using a 10,000 molecular weight cutoff filter (Millipore) and stored at ⫺80 °C.
Assessment of apoE and apoE 25 neurotrophic activities
Full-length recombinant apoE and apoE 25 (1–195 fragment)
were added to SH-SY5Y cells at concentrations of 5 and 20
g/ml 24 h after plating at 10,000 cells/well in a 96-well plate.
The concentration of fetal bovine serum in the cell culture
media was reduced to 1% (v/v), and ATRA was maintained at 10
M. Medium changes (including replenishing r-apoE and
r-apoE 25) were made at 3 days until the final analysis at day 6.
Confluence and neurite length were assessed in five individual
wells every 3 days using an IncuCyte Zoom live cell analysis
system (as described above). Neurite length was measured as
detected by the IncuCyte Zoom software as the total combined
length of all neurites detected per mm2. Cell viability was measured at day 6 using the Presto Blue assay (Thermo Scientific),
following the manufacturer’s instructions.
Statistics
SPSS Statistics software (version 24, SPSS Inc., Chicago, IL)
was used for statistical analysis. All data are expressed as -fold
increase relative to the control (vehicle-treated) group that was
arbitrarily assigned a value of 1.0. Where two groups were compared, a two-tailed t test was used. Where multiple groups were
compared, statistical significance was determined using oneway ANOVA for repeated measures. For all ANOVA testing,
Tukey’s post hoc analysis was used. For both the ANOVA and
the t test, p ⬍ 0.05 was considered significant.
Author contributions—S.S.M., H.L., K.R., and Q.C. data curation;
S.S.M., H.L., K.R., Q.C., A.S., L.O., and B.G. formal analysis; S.S.M.,
H.L., K.R., Q.C., A.S., and B.G. validation; S.S.M., H.L., K.R., Q.C.,
A.S., L.O., and B.G. investigation; S.S.M., H.L., K.R., Q.C., A.S., L.O.,
and B.G. methodology; S.S.M., H.L., K.R., Q.C., A.S., L.O., and B.G.
writing-review and editing; H.L., K.R., and Q.C. visualization; Q.C.,
A.S., L.O., and B.G. resources; A.S., L.O., and B.G. conceptualization;
A.S., L.O., and B.G. supervision; A.S., L.O., and B.G. funding acquisition; B.G. writing-original draft; B.G. project administration.
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used for reverse transcription with an oligo(dT)18 primer
according to the instructions provided with the Tetro cDNA
synthesis kit (Bioline, catalog no. BIO-65043).
Conventional PCR amplification for primer pair checking
was performed using MyTaq HS reagents (Bioline, catalog no.
BIO-25045) and carried out with 30 cycles of denaturation
(95 °C, 15 s), annealing (62 °C, 15 s), and extension (72 °C, 20 s),
and the PCR products were visualized with a Gel Doc 2000
imager system after electrophoresis in 1.5% agarose gels. Quantitative real-time PCR was carried out in a Roche LightCycler威
480 real-time PCR system or Corbett Rotor Gene 3000 system
using the SensiFAST SYBR威 No-ROX kit (Bioline, catalog no.
BIO-98005), following the manufacturer’s protocol. The PCR
program was an initial denaturation step at 92 °C for 2 min,
followed by 40 cycles of denaturation (92 °C for 10 s), annealing
(62 °C for 10 s), and extension (72 °C for 10 s). A final melting
step was performed (95 °C for 5 s, 65 °C for 1 min, and acquiring
continuously until 97 °C). The primer pairs used were as follows: human HTRA1 (HtrA serine peptidase 1, Gene ID 5654),
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